Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928721 | 1.00 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL15249025 | 1.00 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL18118505 | 1.00 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL17463477 | 1.00 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL20010128 | 0.89 | P2RY2 (0.35) | P2RY2 | |
| SCHEMBL15249018 | 0.89 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL17463479 | 0.89 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL18118099 | 0.89 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL14945957 | 0.89 | P2RY2 (0.36) | P2RY2 | |
| SCHEMBL14928661 | 0.89 | P2RY2 (0.36) | P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9587003-B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | MODERNATX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9512456-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160152678-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-02 | — | — | US | disclosed |
| US-9283287-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNA THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9149506-B2 | Modified polynucleotides encoding septin-4 | MODERNA THERAPEUTICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-09-03 | — | — | US | disclosed |
| US-20150211039-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | ARES CAPITAL CORPORATION, AS AGENT | 2015-07-30 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8664194-B2 | Method for producing a protein of interest in a primate | MODERNA THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | P2RY2 4062/4885 |
| US-20150246139-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | P2RY2 3286/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY2 2899/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY2 558/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | P2RY2 3344/4885 |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | POLRMT, POLN, GALNT1 | P2RY2 2757/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | P2RY2 4521/4885 |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | IGF2BP1, PAIP1, PHAX | P2RY2 3872/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | P2RY2 3235/4885 |
| US-20160152678-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | P2RY2 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.